Vanda Pharmaceuticals (VNDA) Receiving Somewhat Negative Press Coverage, Study Shows

Media coverage about Vanda Pharmaceuticals (NASDAQ:VNDA) has been trending somewhat negative this week, according to AlphaOne Sentiment. The research group, a service of Accern, rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a news sentiment score of -0.09 on AlphaOne’s scale. AlphaOne also gave news headlines about the biopharmaceutical company an impact score of 83 out of 100, indicating that recent press coverage is very likely to have an effect on the stock’s share price in the near term.

Here are some of the headlines that may have impacted AlphaOne’s rankings:

Vanda Pharmaceuticals (NASDAQ:VNDA) remained flat at $14.45 during trading on Friday. The company’s stock had a trading volume of 292,126 shares. The company’s market cap is $640.80 million. The company has a 50-day moving average price of $14.20 and a 200 day moving average price of $15.05. Vanda Pharmaceuticals has a 52 week low of $8.04 and a 52 week high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, February 15th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.05. The company had revenue of $38.24 million for the quarter, compared to analyst estimates of $39.38 million. Vanda Pharmaceuticals had a negative net margin of 23.07% and a negative return on equity of 16.13%. Equities analysts predict that Vanda Pharmaceuticals will post ($0.62) EPS for the current year.

VNDA has been the topic of several recent analyst reports. Jefferies Group LLC reissued a “buy” rating and set a $23.00 target price on shares of Vanda Pharmaceuticals in a research note on Sunday, January 8th. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 18th. Oppenheimer Holdings Inc. initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, April 12th. They set an “outperform” rating and a $21.00 target price on the stock. Finally, CIBC reissued an “outperform” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, April 12th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and an average price target of $21.13.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

5 Day Chart for NASDAQ:VNDA

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply